Single dose placebo

DRUG5 trials

Sponsors

Udo Sechtem, C2N Diagnostics, Vanderbilt University, GEN İlaç ve Sağlık Ürünleri A.Ş., Third Harmonic Bio, Inc.

Conditions

Cognitive ImpairmentCoronary VasospasmHealthyHealthy SubjectsProgressive Supranuclear Palsy

Phase 1

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

CompletedNCT02494024

C2N DiagnosticsProgressive Supranuclear Palsy

Start: 2015-07-31End: 2016-08-31Target: 32Updated: 2017-07-26

Putative Cognitive Enhancer VU319

CompletedNCT03220295

Vanderbilt UniversityCognitive Impairment

Start: 2017-07-28End: 2019-10-30Updated: 2020-02-06

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

CompletedNCT06277492

GEN İlaç ve Sağlık Ürünleri A.Ş.Healthy Subjects

Start: 2024-02-19End: 2025-11-27Updated: 2025-12-01

A First in Human Trial Evaluating THB335 in Healthy Participants

CompletedNCT06425861

Third Harmonic Bio, Inc.Healthy

Start: 2024-05-02End: 2024-12-18Updated: 2025-12-19

Phase 3

Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm

WithdrawnNCT00454714

Udo SechtemCoronary Vasospasm

Start: 2007-03-01End: 2009-12-31Updated: 2017-04-12

Related Papers

First‐In‐Human, Single Ascending Dose and Food‐Effect Study in Healthy Volunteers of SUL‐238, a Novel Orally Administered Mitochondria‐Directed Drug Candidate

Alzheimer s & Dementia2025-12-01

Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical Trials

ACS Chemical Neuroscience2024-12-119 citations

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Brain2023-02-02117 citations

O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY

Alzheimer s & Dementia2018-07-012 citations

[O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE

Alzheimer s & Dementia2017-07-0111 citations